Live Quote · NASDAQTELOHealthcare· Biotechnology

Telomir Pharmaceuticals, Inc. Common Stock

$1.27 2.31%($-0.03)
TickerSpark Score
49/100
Weak
50
Valuation
20
Profitability
60
Growth
84
Health
30
Momentum

Built from real-time financials, refreshed daily. For a full Analyst Grade with bull/bear case, price targets, and qualitative risk analysis, generate a TELO research report →

52-Week Range11% of range
Low
$1.05
Current
$1.27
High
$3.10
Company Overviewtelomirpharma.com

About the company

Telomir Pharmaceuticals, Inc. operates as a preclinical-stage pharmaceutical firm, concentrating its efforts on creating and launching novel therapeutic interventions. Its primary focus involves the development of TELOMIR-1, an innovative small molecule compound.

CEO
Erez Aminov
IPO
2019
Employees
1
HQ
Baltimore, FL, US

Price Chart

+7.63% · this period
$2.29$1.69$1.08Jul 02Dec 31Jul 02
Valuation
Market Cap
$43.66M
P/E
-4.32
P/S
0.00
P/B
8.80
EV/EBITDA
-4.15
Div Yield
0.00%
Profitability
Gross Margin
0.00%
Op Margin
0.00%
Net Margin
0.00%
ROE
-201.23%
ROIC
-181.84%
Growth & Income
Revenue
$0 · 0.00%
Net Income
$-10,413,205 · 37.01%
EPS
$-0.33 · 41.07%
Op Income
$-10,538,849
FCF YoY
27.26%
Performance & Tape
52W High
$3.10
52W Low
$1.05
50D MA
$1.29
200D MA
$1.35
Beta
-0.24
Avg Volume
152.68K

Get TickerSpark's AI analysis on TELO

Create an account to generate AI analysis on any ticker — technical setup, analyst consensus, earnings watch, insider pulse, financial health, and peer context. Ready in about a minute.

Get Pro Access →

Already have an account? Log in

Form 4 · Filings

Recent insider transactions

Who's buying, who's selling, and how much.

DateInsiderTypeShares
Jun 3, 26Mushak Andriyother0
May 21, 26Aminov Erezother2,000,000
May 21, 26Aminov Erezother1,960,170
May 21, 26Aminov Erezsell2,000,000
May 21, 26Aminov Erezsell1,960,170
May 21, 26Whalen Matthew Prattother25,000
May 21, 26Whalen Matthew Prattsell25,000
May 21, 26MacPherson Edward Cloustonother25,000
May 21, 26MacPherson Edward Cloustonsell25,000
May 21, 26Del Giudice Matthew Paulother25,000
Coverage · TELO

Our TELO coverage

Recent articles, reports, and earnings notes.

On-Demand Research

No research on TELO yet

For a full analyst-grade research report — grades, price targets, financials, chart analysis — generate one on demand.

Generate TELO report →
Internal Compare

Similar companies

Peers in the same neighborhood.